吉西他滨联合顺铂治疗蒽环类及紫杉醇类耐药的转移性乳腺癌疗效分析

目的观察吉西他滨联合顺铂方案治疗对蒽环类及紫杉醇类均耐药的转移性乳腺癌的疗效及不良反应。方法 36例晚期乳腺癌患者均应用过紫杉醇类及蒽环类药物,采用吉西他滨1000mg/m2静脉注射,第1、8天;顺铂30mg/m2静脉注射第1～3天,21d为1个周期,2个周期后评价疗效,至少应用2个周期。结果 36例中,完全缓解1例(2.8%),部分缓解14例(38.9%),稳定11例(30.6%),进展10例(27.8%),中位疾病进展时间6个月,中位生存时间14个月,1a生存率58%。主要不良反应为骨髓抑制和胃肠道反应。结论吉西他滨联合顺铂对蒽环类及紫杉醇类均耐药的转移性乳腺癌有较好的近期疗效,不良反应能够耐受,是一种效的解救方案。

Clinical Analysis of Gemcitabine Combined with Cisplatin in the Treatment of Metastatic Breast Cancer Patients with Anthracycline and Taxane Resistance

Objective To observe the efficacy and toxicity of gemcitabine and cisplatin combination chemotherapy for anthracycline and taxane-resistant metastatic breast cancer(MBC).Methods Thirty-six patients had failures or relapse after previous treatment with anthracycline and taxane.Gemcitabine and cisplatin were administered by intravenous drip at a dose of 1 000 mg/m2(on day1 and day 8)and 30 mg/m2(from day 1 to day 3),respectively,in a treatment period of 3 weeks. All patients received at least 2 cycles of chem...